Tarlatamab Biosimilar – Anti-GPRC5D/CD3 Bispecific Antibody

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 kappa
Class	Bispecific Antibody
Type	Recombinant Humanized
Conjugate	Unconjugated
Molecular Weight	105.07 kDa
Storage Condition	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.